Dnovobio is a developer of a direct reprogramming technology intended to create any cell, tissue, or organ on demand.
dNovo Bio's investors include Y Combinator, Felicis, Pioneer Fund, Soma Capital, Duro Ventures.
dNovo Bio is headquartered in San Jose, United States.
Dnovobio is a developer of a direct reprogramming technology intended to create any cell, tissue, or organ on demand.
dNovo Bio is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"dNovo Bio — Funding & Investors." VCBacked, January 24, 2022, https://www.vcbacked.co/company/dnovo-bio. Accessed October 31, 2026.
VCBacked. (2022). dNovo Bio — Funding & Investors. Retrieved October 31, 2026, from https://www.vcbacked.co/company/dnovo-bio
{{cite web |title=dNovo Bio — Funding & Investors |url=https://www.vcbacked.co/company/dnovo-bio |website=VCBacked |access-date=October 31, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated